Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
Study Details
Study Description
Brief Summary
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR), inhibiting tyrosine kinase activation. This is a randomized, controlled, open-Label, multicenter, phase Ⅱ clinical trial of nimotuzumab plus Docetaxel and Capecitabine（TX）versus Docetaxel and Capecitabine（TX）as first-line treatment in patients with recurrent/metastatic triple negative breast cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
The control group received docetaxel + capecitabine regimen;Experimental group received Nimotuzumab combined docetaxel + capecitabine regimen.The main purpose is to evaluate Nimotuzumab Plus Docetaxel and Capecitabine（TX）as First-Line Treatment in Patients With Recurrent/Metastatic triple negative breast cancer would improve objective response rate (ORR ) comparing with Docetaxel and Capecitabine（TX）.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Nimotuzumab,docetaxel,capecitabine Nimotuzumab 400mg/w,IV,once a week and Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14 |
Drug: Nimotuzumab
Drug: docetaxel
Drug: capecitabine
|
| Active Comparator: docetaxel,capecitabine Docetaxel 75 mg/m2,IV,D1, every 21 days a cycle and Capecitabine 1000mg/m2, orally, twice daily, D1-D14 |
Drug: docetaxel
Drug: capecitabine
|
Outcome Measures
Primary Outcome Measures
- ORR [every six weeks, up to 1 year]
Evaluation ORR every six weeks,with RECIST 1.1.
Secondary Outcome Measures
- PFS [every six weeks, up to 1 year]
- Number and ratio of AEs [up to 1 year]
Observe and record AEs when AEs occurred
- Relationship of tissue/serum EGFR between efficacy and prognosis [1 year]
every 6 weeks
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Histological and immunohistochemistry (IHC) confirmed recurrent or metastatic triple-negative breast cancer .
-
Previous chemotherapy should include anthracycline or taxane; No prior chemotherapy after metastasis.
-
Females with age between 18 and 70 years old
-
ECOG performance status 0 or 1.
-
At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST) by magnetic resonance imaging, or computed tomography; The target lesions is Unresectable; The target lesions did not receive radiotherapy or relapse within the radiation field;
-
Life expectancy ≥ 12 weeks.；
-
WBC count ≥ 4 × 109 / L, neutrophils ≥ 1.5 × 109 / L, platelet count ≥ 100 × 109 / L, hemoglobin ≥ 6.21mmol / L (10 g / dL);
-
Total bilirubin (TBL)≤ 1.5 x ULN (upper limit of normal reference values); AST and ALT ≤ 2.5 x ULN or ≤ 5 ULN (Liver metastasis);Serum creatinine ≤ 1.5 x ULN.
-
Before enrollment, patients have fully recovered from previous treatment-related toxicity;
-
Subjects with fertility must accept effective contraceptive measures;
-
Signed informed consent
Exclusion Criteria:
-
Previously treatment regimen including anti EGFR monoclonal antibody;
-
Receiving other anti-cancer medicine treatment during the study
-
Participate in other clinical trials within 4 weeks in this group;
-
Accepted taxane treatment in 1 year;
-
Presence of neurological symptoms due to brain metastasis, patients receiving steroidal anti-edema drugs therapy;
-
Patients having a history of clinically significant symptomatic angina, arrhythmia or congestive heart failure without control;
-
Diagnosed with severe interstitial pneumonitis or pulmonary fibrosis by chest CT;
-
Pleural effusion, ascites require to be drained;
-
Adverse drug addiction and drug abuse, long-term alcoholics, as well as AIDS patients; patients with severe or uncontrolled complications, such as infection requiring systemic therapy, fever (≥ 38 ℃), diabetes or hypertension can not be controlled by medicine, other complications may interfere with drug therapy;
-
Patients with a history of drug allergy (≥ CTCAE 2 level) such as shock or allergic symptoms, especially have allergic reactions to similar drugs in the past, have severe allergies reactions to drugs containing polysorbate eighty (Tween 80);
-
Uncontrolled seizures or loss of insight due to mental disorders;
-
Pregnant or lactating women；
-
Researchers think improper for this trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Beijing | Beijing | China | 100021 |
| 2 | Beijing cancer hospital | Beijing | Beijing | China | 100142 |
| 3 | The General Hospital of the People's Liberation Army (PLAGH) | Beijing | Beijing | China | |
| 4 | Harbin Medical University Cancer Hospital | Harbin | Heilongjiang | China | |
| 5 | Liaoning Cancer Hospital and Institute | Shenyang | Liaoning | China | |
| 6 | FuDan University Shanghai Cancer Center | Shanghai | Shanghai | China | |
| 7 | Xijing Hospital | Xi-an | Shanxi | China | 710032 |
| 8 | The First Affiliated Hospital of College of Medicine, Zhejiang University (First Hospital of Zhejiang Province) | Hangzhou | Zhejiang | China | |
| 9 | Zhejiang Cancer Hospital | Hangzhou | Zhejiang | China |
Sponsors and Collaborators
- Chinese Academy of Medical Sciences
- Biotech Pharmaceutical Co., Ltd.
Investigators
- Principal Investigator: Binghe Xu, Cancer Insititute and Hospital, CAMS
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- BT-BC-001